provider
Search result for "Solr search content"
Search Result for "Prostate Cancer"
Clinical Trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (CTMS# 18-0071)
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)
provider
Dharam Kaushik, M.D. Urology Oncology, Urology
Our Cancer Programs
Our Cancer Programs
provider
Daruka Mahadevan, MD, PhD Hematology Oncology, Phase I Clinical Trials
provider
John Sarantopoulos, MD Medical Oncology, Internal Medicine
provider